MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer
Brian metastasis, which is diagnosed in 30% of triple-negative breast cancer (TNBC) patients with metastasis, causes poor survival outcomes. Growing evidence has characterized miRNAs involving in breast cancer brain metastasis; however, currently, there is a lack of prognostic plasma-based indicator for brain metastasis. In this study, high level of miR-211 can act as brain metastatic prognostic marker in vivo. High miR-211 drives early and specific brain colonization through enhancing trans-blood-brain barrier (BBB) migration, BBB adherence, and stemness properties of tumor cells and causes poor survival in vivo. SOX11 and NGN2 are the downstream targets of miR-211 and negatively regulate miR-211-mediated TNBC brain metastasis in vitro and in vivo. Most importantly, high miR-211 is correlated with poor survival and brain metastasis in TNBC patients. Our findings suggest that miR-211 may be used as an indicator for TNBC brain metastasis.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
---|---|
Enthalten in: |
Oncogene - 40(2021), 9 vom: 03. März, Seite 1737-1751 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pan, Jhih-Kai [VerfasserIn] |
---|
Links: |
---|
Themen: |
Basic Helix-Loop-Helix Transcription Factors |
---|
Anmerkungen: |
Date Completed 29.07.2021 Date Revised 31.07.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41388-021-01654-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM320973298 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM320973298 | ||
003 | DE-627 | ||
005 | 20231225174821.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41388-021-01654-3 |2 doi | |
028 | 5 | 2 | |a pubmed24n1069.xml |
035 | |a (DE-627)NLM320973298 | ||
035 | |a (NLM)33536579 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pan, Jhih-Kai |e verfasserin |4 aut | |
245 | 1 | 0 | |a MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.07.2021 | ||
500 | |a Date Revised 31.07.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Brian metastasis, which is diagnosed in 30% of triple-negative breast cancer (TNBC) patients with metastasis, causes poor survival outcomes. Growing evidence has characterized miRNAs involving in breast cancer brain metastasis; however, currently, there is a lack of prognostic plasma-based indicator for brain metastasis. In this study, high level of miR-211 can act as brain metastatic prognostic marker in vivo. High miR-211 drives early and specific brain colonization through enhancing trans-blood-brain barrier (BBB) migration, BBB adherence, and stemness properties of tumor cells and causes poor survival in vivo. SOX11 and NGN2 are the downstream targets of miR-211 and negatively regulate miR-211-mediated TNBC brain metastasis in vitro and in vivo. Most importantly, high miR-211 is correlated with poor survival and brain metastasis in TNBC patients. Our findings suggest that miR-211 may be used as an indicator for TNBC brain metastasis | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Basic Helix-Loop-Helix Transcription Factors |2 NLM | |
650 | 7 | |a MIRN211 microRNA, human |2 NLM | |
650 | 7 | |a MicroRNAs |2 NLM | |
650 | 7 | |a NEUROG2 protein, human |2 NLM | |
650 | 7 | |a Nerve Tissue Proteins |2 NLM | |
650 | 7 | |a SOX11 protein, human |2 NLM | |
650 | 7 | |a SOXC Transcription Factors |2 NLM | |
700 | 1 | |a Lin, Cheng-Han |e verfasserin |4 aut | |
700 | 1 | |a Kuo, Yao-Lung |e verfasserin |4 aut | |
700 | 1 | |a Ger, Luo-Ping |e verfasserin |4 aut | |
700 | 1 | |a Cheng, Hui-Chuan |e verfasserin |4 aut | |
700 | 1 | |a Yao, Yun-Chin |e verfasserin |4 aut | |
700 | 1 | |a Hsiao, Michael |e verfasserin |4 aut | |
700 | 1 | |a Lu, Pei-Jung |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Oncogene |d 1990 |g 40(2021), 9 vom: 03. März, Seite 1737-1751 |w (DE-627)NLM012595683 |x 1476-5594 |7 nnns |
773 | 1 | 8 | |g volume:40 |g year:2021 |g number:9 |g day:03 |g month:03 |g pages:1737-1751 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41388-021-01654-3 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 40 |j 2021 |e 9 |b 03 |c 03 |h 1737-1751 |